NasdaqGS - Nasdaq Real Time Price USD

Illumina, Inc. (ILMN)

124.46

+4.21

(+3.50%)

At close: 4:00 PM EDT

124.41

-0.05

(-0.04%)

After hours: 5:58 PM EDT

Illumina (NASDAQ:ILMN) investors are sitting on a loss of 71% if they invested three years ago

As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses...

Simply Wall St. 11 hours ago

ILMN
+3.50%
This CEO has battled billionaire activist Carl Icahn twice — here's his advice to Disney CEO Bob Iger

Illumina chairman and Hologic CEO Stephen MacMillan is no stranger to dealing with well-known activist investors.

Yahoo Finance 2 days ago

ILMN
+3.50%
SYK

DIS
20 Countries with the Highest Cancer Survival Rates in the World

In this article, we will be taking a look at the 20 countries with the highest cancer survival rates in the world. If you do not want to learn about the cancer treatment in the US, head straight to the 5 Countries with the Highest Cancer Survival Rates in the World. Navigating the Terrain: The […]

Insider Monkey 4 days ago

ILMN
+3.50%
AZN
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks 4 days ago

ILMN
+3.50%
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks 4 days ago

ILMN
+3.50%
Engineering a Cool Career in Biotech - and Volunteering Along the Way

What kind of opportunities can an engineer find through their work? Plenty, at Illumina! One employee shares how she makes a difference. Originally published on Illumina News Center NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Inside a lab that ...

ACCESSWIRE 5 days ago

ILMN
+3.50%
QQQ Has Some Inexpensive Growth Stocks

As home to an array of storied growth stocks, the Nasdaq-100 Index (NDX) usually isn’t viewed as a bargain hunter’s paradise. That view is usually accurate. But it also belies the fact that, upon closer inspection, the benchmark is home to some attractively valued stocks. That’s encouraging news for investors considering the Invesco QQQ Trust [...]

ETF Trends 5 days ago

ADBE

ILMN
+3.50%
Evidence Supports Sequencing As First-Line Rare Disease Diagnostic

The Medical Genome Initiative presents a paper in an effort to expand patient access to sequencing Originally published on Illumina News Center NORTHAMPTON, MA / ACCESSWIRE / April 17, 2024 / A recent literature review, published in the Nature journalGenomic ...

ACCESSWIRE 6 days ago

ILMN
+3.50%
European Commission approves Illumina’s proposed Grail split

Selling Grail to a third party would free Illumina of the need to capitalize the company, but the buyer would need the commission’s approval, analysts wrote.

MedTech Dive 8 days ago

ILMN
+3.50%
Illumina's planned divestment of GRAIL approved by the European Commission

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC).

PR Newswire 11 days ago

ILMN
+3.50%
UPDATE 2-EU approves Illumina's plan to divest cancer test maker Grail

U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.

Reuters 11 days ago

ILMN
+3.50%
EU approves Illumina's plan to divest cancer test maker Grail

BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.

Reuters 11 days ago

ILMN
+3.50%
Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure

Investors shelved their hopes for a pioneering cancer blood test after Illumina ‘s $8 billion acquisition of start-up Grail was scuttled by antitrust regulators last year. A decade from now, these blood tests could be used to flag the more than 60% of deadly cancers that currently lack any way to screen for them. At the annual meeting of the American Association for Cancer Research in San Diego, Exact Sciences reported on a 6,000-sample study of a multi-cancer test it plans to offer alongside single-cancer screening products such as its well-known Cologuard stool-based test for colon cancer.

Barrons.com 13 days ago

ILMN
+3.50%
EXAS
+1.79%
Illumina CFO steps down amid executive shakeup

Ankur Dhingra, who worked with Illumina’s CEO at Agilent Technologies, is joining the genome sequencing company to replace Joydeep Goswami.

MedTech Dive 13 days ago

ILMN
+3.50%
A
UPDATE 2-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Illumina said on Tuesday Chief Financial Officer Joydeep Goswami will leave the gene sequencing company and be succeeded by former Summit Therapeutics' executive Ankur Dhingra. Goswami, who has more than two decades of experience in the life sciences industry, was the CFO since early 2023 and will serve as an adviser till June 30, the company said. Prior to Summit, Dhingra was the CFO at medical test maker CareDx.

Reuters 14 days ago

ILMN
+3.50%
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Goswami, who has more than two decades of experience in the life sciences industry, was the CFO since early 2023 and will serve as an adviser till June 30, the company said. Prior to Summit, Dhingra was the CFO at medical test maker CareDx. Illumina has also reaffirmed its forecast for the first quarter and full-year 2024.

Reuters 14 days ago

ILMN
+3.50%
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.

PR Newswire 14 days ago

ILMN
+3.50%
Nasdaq’s Nosebleed Section: 3 Expensive Stocks to Sell Before It’s Too Late

The stock market has been in a solid rally since the third quarter of 2023, pushing significant indices to new highs. That upward trajectory also raised company valuations for many stocks, putting investors at risk of inflated stock prices and selloffs. Being the most traded exchange in the states, the Nasdaq is no stranger to seeing expensive stocks that investors should sell. These expensive stocks show signs of decline or have recently seen explosive price growth that lacks fundamental suppor

InvestorPlace 18 days ago

MDB

ILMN
+3.50%
Why More Clinical Labs Are Turning to Whole-Genome Sequencing for Cancer

NORTHAMPTON, MA / ACCESSWIRE / April 5, 2024 / Illumina The adoption of WGS in precision oncology is on the rise. Plus: the promise of MRD Originally published on Illumina News Center Whole-genome sequencing (WGS) use is more established for rare ...

ACCESSWIRE 18 days ago

ILMN
+3.50%
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024

Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, 2024.

PR Newswire 19 days ago

ILMN
+3.50%

Performance Overview

Return	ILMN	S&P 500
YTD	-10.61%	+6.30%
1-Year	-45.34%	+22.67%
3-Year	-69.53%	+22.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Illumina, Inc. (ILMN)

Illumina (NASDAQ:ILMN) investors are sitting on a loss of 71% if they invested three years ago

This CEO has battled billionaire activist Carl Icahn twice — here's his advice to Disney CEO Bob Iger

20 Countries with the Highest Cancer Survival Rates in the World

Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Engineering a Cool Career in Biotech - and Volunteering Along the Way

QQQ Has Some Inexpensive Growth Stocks

Evidence Supports Sequencing As First-Line Rare Disease Diagnostic

European Commission approves Illumina’s proposed Grail split

Illumina's planned divestment of GRAIL approved by the European Commission

UPDATE 2-EU approves Illumina's plan to divest cancer test maker Grail

EU approves Illumina's plan to divest cancer test maker Grail

Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure

Illumina CFO steps down amid executive shakeup

UPDATE 2-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

Nasdaq’s Nosebleed Section: 3 Expensive Stocks to Sell Before It’s Too Late

Why More Clinical Labs Are Turning to Whole-Genome Sequencing for Cancer

Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024

Performance Overview